Levodopa and Benserazide Hydrochloride Tablets
This product is a compound preparation, and its components are: each tablet contains levodopa 200mg and benzetharate 50mg (equivalent to benzethazine hydrochloride 57mg).
Indications:
It is used for the treatment of Parkinson's disease, symptomatic Parkinson's disease (post-encephalitis, arteriosclerotic or toxic), but does not include drug-induced Parkinson's disease.
Adverse reactions:
1. Blood and lymphatic system: hemolytic anemia, transient leukopenia and thrombocytopenia have been reported in very few cases. Therefore, during long-term treatment with levodopa-containing drugs, blood cells and liver and kidney function should be checked regularly. 2. Metabolism and nutrition: anorexia has been reported. 3. Psychiatric symptoms: Depression may occur in patients treated with Medopa, but this may also be a clinical manifestation in patients with Parkinson's disease and hyperactive leg syndrome. Agitation, anxiety, insomnia, hallucinations, delusions, and transient disorientation may occur in older patients or those with similar medical history. 4. Nervous system: individual cases have reported loss of taste or dysgeusia. Later in treatment, dyskinesia (e.g., chorea-like movements or athetosis) may occur, and reducing the dose usually resolves symptoms.
Contraindications:
1. Medopar is contraindicated in patients who are known to be allergic to levodopa, benserazide or their excipients. 2. It is forbidden to combine medopar with non-selective monoamine oxidase inhibitors, but selective monoamine oxidase B inhibitors (such as selegiline and rasagiline) and selective monoamine oxidase A inhibitors (such as moclobemide) are not prohibited. The combination of monoamine oxidase A and monoamine oxidase B inhibitors is equivalent to a non-selective monoamine oxidase inhibitor and should not be used in combination with medopar (see Drug Interactions). 3. Medopa is contraindicated in patients with endocr
ine, renal (except dialysis), hepatic function compensation or heart disease, psychosis, and angle-closure glaucoma. 4. Medopa is contraindicated in patients under 25 years of age (must be patients with complete skeletal development). 5. Medopa is contraindicated in women who are pregnant and who are not using effective contraception and who are potentially pregnant (e.g., pregnant or lactating women). If the patient becomes pregnant while taking the medication, the medication should be discontinued (as recommended by the prescribing physician).
Shijiazhuang No. 4 Pharmaceutical Co., Ltd., as one of the leading manufacturers in Chinese pharmaceutical industry and a well-known brand, has a business history of seventy years. The company principally specializes in R & D, manufacture and sales of wide types of drugs mainly including intravenous infusion.
For the key product of large volume I.V solution, the yearly output has reached more than 1.5 billion bottles including 1 billion packing with the soft plastic bottles and plastic bags in the dosage of 500 ml/ 250 ml /100ml. Some index such as quality, variety, and yearly output are all in the leading position of this field in China. The products have been sold to some countries and regions in South America, Africa, and Asia.
Audited Supplier 
){kind=link}